您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Flunisolide hemihydrate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Flunisolide hemihydrate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Flunisolide hemihydrate图片
CAS NO:77326-96-6
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品名称
氟尼缩松半水合物
产品介绍
Flunisolide hemihydrate 是一种皮质类固醇,是具有口服活性的糖皮质激素受体 (Glucocorticoid receptor) 激活剂,具有抗炎活性。Flunisolide hemihydrate 可诱导嗜酸性粒细胞凋亡 (apoptosis),可用于哮喘或鼻炎、炎症的相关研究。
生物活性

Flunisolide hemihydrate is a corticosteroid, which is an orally activeglucocorticoid receptoractivator withanti-inflammatoryactivity. Flunisolide hemihydrate can induce eosinophilapoptosis, and is used for the research of asthma or rhinitis, and inflammation[1][2].

体外研究
(In Vitro)

Flunisolide hemihydrate (0.1-10 μM, 1 h) inhibits lung fibroblast (Isolated from lung) activation[1].
Flunisolide hemihydrate (10 μM, 24 h) reduces MMP-9, TIMP-1, TGF-β and fibronectin release by sputum cells (isolated from mild to moderate asthmatics), and induces sputum eosinophil apoptosis[2].
Flunisolide hemihydrate (0.1-10 μM μM, 24 h) effectively inhibits ICAM-1 expression and GM-CSF and IL-5 release induced by TNF-alpha in BEAS-2B cells[3].
Flunisolide hemihydrate (115 μM, 0-3 h) can be transported in a polarized way in the apical (ap) to basolateral (bl) direction in Calu-3 cells and is demonstrated to be ATP-dependent[4].

Apoptosis Analysis[2]

Cell Line:Eosinophil
Concentration:10 μM
Incubation Time:24 h
Result:Induced sputum eosinophil apoptosis.
体内研究
(In Vivo)

Flunisolide hemihydrate (Intranasal administration, 0.3-10 μg/mouse, daily, from days 21–27) inhibits lung inflammation, fibrosis, and airway hyper-reactivity, also improves clearance of silica particles from the lungs in silicotic mice[1].
Flunisolide hemihydrate (Intranasal administration, 0.3-10 μg/mouse, daily, from days 21–27) inhibits silica-induced macrophage and myofibroblast accumulation in the lung tissue[1].

Animal Model:Male Swiss Webster mice (instilled, intranasally, with crystalline silica, 10 mg/50 μL, particle size 0.5-10 μm)[1]
Dosage:0.3-10 μg/mouse, daily, from days 21-27
Administration:Intranasal administration
Result:Reduced both granulomatous response, collagen deposition, concerning granuloma formation caused by silica particles.
Reduced the number of F4/80 and α-SMA positive cells.
Clinical Trial
分子量

443.51

Formula

C24H33FO7

CAS 号

77326-96-6

中文名称

氟尼缩松半水合物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.